000 | 01652 a2200457 4500 | ||
---|---|---|---|
005 | 20250516185522.0 | ||
264 | 0 | _c20140723 | |
008 | 201407s 0 0 eng d | ||
022 | _a0392-856X | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPrete, M | |
245 | 0 | 0 |
_aSevere pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. _h[electronic resource] |
260 |
_bClinical and experimental rheumatology _c |
||
300 |
_a267-74 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Journal Article; Review | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntibodies, Antiphospholipid _xblood |
650 | 0 | 4 |
_aAutoimmunity _xdrug effects |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 | _aClinical Trials as Topic |
650 | 0 | 4 |
_aCyclosporine _xadministration & dosage |
650 | 0 | 4 |
_aDelayed Diagnosis _xprevention & control |
650 | 0 | 4 | _aDisease Management |
650 | 0 | 4 |
_aEndothelin-1 _xblood |
650 | 0 | 4 | _aFamilial Primary Pulmonary Hypertension |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypertension, Pulmonary _xdrug therapy |
650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xcomplications |
650 | 0 | 4 |
_aMycophenolic Acid _xadministration & dosage |
650 | 0 | 4 | _aPredictive Value of Tests |
650 | 0 | 4 |
_aRheumatoid Factor _xblood |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aFatone, M C | |
700 | 1 | _aVacca, A | |
700 | 1 | _aRacanelli, V | |
700 | 1 | _aPerosa, F | |
773 | 0 |
_tClinical and experimental rheumatology _gvol. 32 _gno. 2 _gp. 267-74 |
|
999 |
_c23379929 _d23379929 |